

*Review Article***Immunocontraceptive Vaccine- An Ore to Be Mined****K. Rajamanickam*, S. Gowrishankar¹ and V. Leela**

Department of Veterinary Physiology, Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu, INDIA

¹Department of Veterinary Parasitology***Corresponding author:** rajapk92@gmail.com

Rec. Date:	Oct 16, 2017 02:27
Accept Date:	Mar 24, 2018 08:28
DOI	10.5455/ijlr.20171016022732

Abstract

Immunocontraception is the novel contraceptive approach, which uses body immune system to elicit an immune response to wedge the important steps in reproduction and reduce the fertility rate in vaccinated animals. Immunocontraceptives are developed mainly to target the three main areas of reproductive process namely gamete production, gamete function and gamete outcome. Contraceptive vaccines, which antagonize the effect of gonadotropin-releasing hormone (GnRH), follicular stimulating hormone (FSH) and luteinizing hormone (LH) have been tested in various species including dogs and cats. GnRH based vaccines are used for immune-castration of pigs to reduce the boar taint, which devalues the pork. Vaccines acting through the sperm-specific proteins and zona pellucida (ZP) glycoproteins have a greater advantage because of their high specificity to the germ cells. Immunization of dogs with native porcine ZP inhibit the fertility associated with ovarian dysfunction. Production of the monoclonal antibody against these proteins have added the advantage in immunocontraception. Recombinant ZP vaccines produced using Escherichia coli have reduced cross-reactivity with the somatic cells and impart long-term infertility. In spite of these advantages, immunocontraceptives may develop resistance in the immunized population in future, so more scientific inputs are required to increase the immunogenicity of immunocontraceptive vaccines and the novel vaccine delivery methods need to be developed which would impart long-term infertility with a single injection.

Key words: Immunocontraceptive Vaccine, Immune Response, Infertility, GnRh, ZP, Population Control**How to cite:** Kandasamy, R., Shanmugam, G., & Venkatasubramanian, L. (2018). Immunocontraceptive Vaccine- an Ore to be Mined. International Journal of Livestock Research, 8(8), 9-20. doi: 10.5455/ijlr.20171016022732**Introduction**

Traditionally, vaccines are used to impart immunity against various pathogens and protect animals from various diseases. Later, the approach was changed, scientists started to develop vaccines against diseases like cancer, autoimmune disorders, etc., as a therapeutic option and also aimed to neutralize negative

factors against growth to promote growth in broilers by active immunizing against somatostatin (Guo *et al.*, 2013 and Anderson and Jabri, 2013). Recently, the trend was changed because the vaccines have been developed to impart infertility (contraception) in both animals and humans (Gupta *et al.*, 2014). Contraceptive vaccines are proposed to control population explosion, to prevent human-animal conflicts and to prevent zoonoses. In this kind of approach, preformed antibodies are produced to act on multiple targets and thus preventing fertilization. A contraceptive vaccine uses the host defence mechanism as a weapon to attack the normal reproductive functions as described Frayne and Hall (1999). When a contraceptive a vaccine is said to be successfully developed, it should meet the following criteria; it must be widely accepted, safe, easy to administer, affordable, reliable and should impart homogenous immune response in the subjects. Basically, contraceptive vaccines are of three types, I) acting on gamete production, II) acting on gamete function and III) acting on gamete outcome (Naz *et al.*, 2005).

Immunocontraception – A Concept of Magic Bullet

A novel approach developed in population control methods is “immunocontraception”. Immunocontraceptives are vaccines that produce an adaptive immune response which makes the animal infertile. In various developing countries, the spread of zoonotic diseases is of increasing concern now and stray dogs are the important niche for the diseases like rabies. To control the population of stray dogs, castration and spaying are employed now but they are time-consuming and laborious in nature. In this regard herd immunization with the immunocontraceptive vaccines provide a better alternative approach. Comparing with other methods of population control, immunocontraceptives have ample advantages like long-term action, reduced endocrine disturbances have limited the need for implants and surgeries, etc., (Naz, 2011). Now researchers are focused on developing an immunocontraceptive vaccine which produces long-term infertility with single dose itself.

Immunocontraceptives Affecting Gamete Production

In reproductive physiology, gonadotropin-releasing hormone (GnRH) plays an important role. GnRH is produced from median eminence of hypothalamus and regulates the release of the follicular stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary gland. They act on the gonads and regulates the production of gametes in both male and female animals. Immunoneutralization of these hormones will culminate the production of gametes by acting through ligand-receptor interactions. Immunocontraceptive vaccines which act on the gamete production are mainly of three types namely, GnRH based, FSH based and LH based immunocontraceptive vaccines Satish and Vidisha (2017).

GnRH Based Immunocontraceptive Vaccines

Gonadotropin-releasing hormone is a decapeptide, that causes the release of gonadotropins in both the sexes. Hence a vaccine against GnRH can prevent fertilization in both male and female animals. GnRH has a main role in the hypothalamic-pituitary-gonadal axis besides its many extrapituitary functions in testis, prostate and placenta (Naz, 2006). GnRH vaccines are validated on human subjects by the National Institute of Immunology, India, but the demerits have casted doubts for being used as a vaccine candidate (Schrater, 1995). Carrier proteins are antigenic molecules which are covalently attached to a poor antigen elicit a stronger immune response. Carrier proteins employed in the vaccine production play a major role in imparting antigenicity of the vaccine (Rino and Fabio, 2011). This is yet another area of focus to improve the efficacy of the vaccine. Initially various carrier proteins like diphtheria toxoid (DT) (Gupta *et al.*, 2014), Tetanus Toxoid (TT) (Hodges and Hearn, 1977), mycobacterium tuberculosis hsp 70 (Hannesdottir *et al.*, 2004), keyhole limpet hemocyanin (Miller *et al.*, 2000), thioredoxin (Stevens *et al.*, 2005) and ovalbumin (Gupta *et al.*, 2014), were used in the production of vaccine but they imparted low antibody titre even after repeated injections. Diwan *et al.* (1998) and Ferro *et al.* (2004), tried an alternative approach with many adjuvant proteins/ peptides like Quil A, Aluminium hydroxide, polylactide co glycolide acid (PLGA), etc., among them GnRH-TT in polylactide co glycolide acid (PLGA) microspheres produced an effective immune response within 15 days of immunization, thus it nullifies the need of repeated injections. Vaxstrate, Improvac, Bopriva, Gonacon-Blue, Repro-BLOC, etc., are the few GnRH based contraceptives vaccines available in the market, but research is still on pipeline to evolve potential vaccines Kaur and Prabha (2014). Miller *et al.* (2013) described the GonaCon™ a commercial GnRH based contraceptive vaccine, consists of synthetic GnRH conjugated to KLH(blue protein from mollusc) developed by National Wildlife Research Center, USA, which was approved by Environment Protection Agency (EPA), USA for its use in white-tailed deer, burros and wild horse, which imparts two to five years of infertility in white-tailed deer by single injection itself, (Miller *et al.*, 2008). Benka and Levy (2015) validated the contraceptive efficacy of this vaccine was in cats also, where it produced infertility for about five months to five years depending upon the immune response developed in the respective queen or tom cats upon single injection. Massei *et al.* (2015) conducted a study using GnRH vaccine (Gonacon) to control the ferrel cattle population in Hong Kong to reduce the human-animal conflicts. The efficacy of the vaccine was assessed by measuring the anti-GnRH antibodies produced in the vaccinated herd. The results were on the positive side to make this vaccine as a commercial product. Improvac® is a GnRH based contraceptive vaccine, immunization of the Iberian female pigs reduced the incidence of standing oestrus, physiological competence of uterus and ovaries and serum progesterone level. After the third injection with Improvac®, 20 months of long-lasting immunity was observed in these pigs Dalmau *et al.* (2015). After injection of Improvac® in male pigs

significant reduction in their sexual and aggressive behaviour was observed (Karaconji *et al.*, 2015). Active immunization of pubertal bulls with Bopriva® a GnRH based contraceptive vaccine, reduced the blood testosterone level, aggression and testicular growth Janet *et al.* (2012). In female dairy cattle, Bopriva® produces a significant reduction in the blood progesterone level, suppression of oestrus and reduced folliculogenesis (Balet *et al.*, 2014). Improvest®, an another commercial vaccine based on GnRH vaccine, which was used for immuno-castration in male pigs and to improve the meat quality by reducing the boar taint Lugar *et al.* (2017). In gilts this vaccine improved the growth performance and reduced the oestrus Bohrer *et al.* (2014). In general, loss of hair, atrophy of prostate, impotency after chronic exposure, inability to induce spermiation and abortion in pregnant animals in vaccinated subjects were considered to be a negative aspect of GnRH based immunocontraceptives.

FSH Based Immunocontraceptive Vaccines

Follicle stimulating hormone has two subunits alpha (α) and beta (β). It plays an important role in maintenance of spermatogenesis. Binding of FSH to the receptor is mediated by beta subunits. Researchers had exploited this function as a contraceptive in males. Mainly, antibodies developed against the ovine FSH was used as contraceptives in other species (Moudgal *et al.*, 1992), because the ovine FSH has the property of cross-reactivity with the FSH of other species including humans (Moudgal *et al.*, 1997). An added advantage in using the FSH based vaccine is, they will not react with LH and Thyroid Stimulating Hormone because of structural similarity with alpha subunit Moudgal *et al.* (1992). Moudgal *et al.* (1997) immunized male bonnet monkeys with the ovine FSH, they had no significant effect on blood testosterone level and they were reported with normal libido. When these animals were used for mating, they failed to impregnate the counterparts because this vaccine affects the spermatogenesis and reduces the fertility rate. But the immunized animals regained the fertility, when there was a decline in the anti-ovine FSH antibody level. To overcome this, scientists used FSH coding peptides for both priming and boosting instead of using native protein form. In this peptide – prime-boost strategies, there was also a reduction in the pathology of seminiferous tubules and interstitial cells Yang *et al.* (2011).

LH Based Immunocontraceptive Vaccines

Luteinizing hormone is the heterodimeric glycoprotein produced by the anterior pituitary gland. Main functions include induction of ovulation, corpus luteum development in females and production of testosterone in males. It is also called as interstitial cell-stimulating hormone in males. LH has one α and one β subunits. In ovine model, use of LH based vaccine inhibited the pregnancy for two breeding seasons. This is because of absence of ovulatory surge to induce ovulation. LH based contraceptives affect the production of sex steroids and lead to impotence in many subjects, this is considered to be a

vital demerit in its usage Roberts and Reeves (1989). In another study by Remy *et al.* (1993), prepubertal male mice was immunized with baculovirus-expressed recombinant porcine LH receptor proteins showed significant reduction in spermatogenesis and testosterone level. The immunized mice had reduced fertility levels up to 75 percentage.

Sperm and Egg Specific Protein-Based Immunocontraceptive Vaccines

Successful interaction of sperm and egg is important for the formation of zygote. This process of interaction/fertilization is mediated by the specific proteins located on the egg and sperm cells. Immunocontraceptive vaccines have been developed to target these specific proteins present in both sperm and zona antigens of egg. In case of egg-specific proteins, zona pellucida proteins are exploited more for this purpose. In males, various sperm-specific proteins are identified and they are utilized for the production of immunocontraceptive vaccines. Less cross-reactivity with the somatic cell proteins and being non hormonal are the important hallmark of this type of vaccines.

Zona Pellucida (ZP) Proteins as Contraceptives

Zona pellucida (ZP) protein is a thick, translucent, glycoprotein present in the extracellular matrix of the oocyte. ZP protein serves as a docking site for recognition and tissue specificity. ZP protein serves as a potential candidate in mediating fertilization process and for the sperm to bind with the oocyte. Post-translational modification of ZP leads to the formation of different families of Zona pellucida protein namely, ZP1, ZP2, ZP3 and ZP4 (Gupta *et al.*, 2003). ZP vaccines elicit humoral and/or cell-mediated immune response to inhibit the attachment of sperm to ovum because the binding sites are already occupied by the antibodies produced against the ZP protein in the immunized individuals. Inhibition of folliculogenesis in immunized individuals was due to immune response mediated by oophoritogenic T – cell epitopes (Satish *et al.*, 2011). ZP proteins also show cross-species reactivity (Kaur and Prabha, 2014). In rabbit model, infertility induced by the ZP vaccine is irreversible due to destruction of oocytes in all growing follicles Skinner *et al.* (1984). This shows another mechanism by which ZP vaccines induce the infertility apart from affecting sperm-egg interaction. Immunization of mare with native porcine ZP vaccine inhibited the anti-Mullerian hormone production and caused the suppression of ovarian follicular development and follicular function (Joone *et al.*, 2018). Initially, active immunization with native porcine ZP glycoproteins in both total solubilized and purified forms were employed to study the contraceptive potential of ZP proteins (Wood *et al.*, 1981). Mahi-Brown *et al.* (1982) demonstrated the use of total solubilized ZP proteins produced infertility but there was a significant side effect like abnormal cycles and ovarian pathology. These side effects were due to the contamination with other ovary associated proteins, also mediated by cytotoxic T lymphocytes and the use of Freund's adjuvants

(Joone *et al.*, 2017). To reduce the side effects, the purified ZP glycoproteins including individual porcine ZP glycoproteins were developed without having any contamination with ovary associated proteins (Yurewicz *et al.*, 1987). *Escherichia coli* expressed recombinant dog ZP3 vaccine produced infertility in three out of four immunized dogs which was due to follicular atresia and atretic changes in ZP protein without any side effects (Santhanam *et al.*, 1998 and Srivastava *et al.*, 2002). To enhance the efficacy of ZP vaccine various strategies have been implemented they were-

- 1) Designing the immunogen by using multiple B epitope of single ZP or single epitope of multiple ZP proteins, this strategy inhibited the estrus in female dogs for longer time than usual (Cui *et al.*, 2010).
- 2) Altering the preparation methods of ZP vaccine like making microspheres using PLGA (poly D, L-Lactide-co-glycolide) (Kanchan and Panda, 2007), using the virus-like peptides (Grgacic and Anderson, 2006) and bacterial ghost (Walcher *et al.*, 2008) and using live vectors like attenuated *Salmonella typhimurium* (Zhang *et al.*, 1997).
- 3) DNA vaccine encoded with ZP protein sequence, these DNA based vaccines produced the bioactive antibodies (Leitner *et al.*, 1999). ZP based vaccines have non-hormonal actions, so they find greater utility and lesser side effects in contraceptive development. But ZP vaccines also have drawbacks like they can have contamination with ovarian associated proteins, batch to batch variation and limited ZP glycoprotein from native source.

Sperm Antigens as Contraceptive Vaccines

A contraceptive vaccine based on the sperm proteins is a promising candidate in developing an effective immunocontraception. Sperm has both iso and autoantigens in it, so cross immunization will produce anti-sperm antibodies (ASA) which reduces fertility. Successful fertilization of the oocyte by sperm depends on various factors like motility, viability, defects, capacitation and acrosomal reactions, penetration of ZP proteins and fusion with ovum. When any one of the above said phenomenon is targetted using specific antibodies, infertility is achieved. Sperm contains different types of proteins like sperm adhesion molecule (SPAM-1) (Cherr *et al.*, 2001), metalloprotease disintegrin cysteine (MDC) (Nishimura *et al.*, 2004), sperm protein (SP-10) (Herr *et al.*, 1990), fertilization antigen (FA-1) (Naz *et al.*, 1984), Sperm protein – 17 (O’Rand and Porter, 1982), sperm agglutination antigen (SGA-1) (Diekman *et al.*, 1997), sperm acrosomal membrane associated protein (SAMP-32) (Rao *et al.*, 2003) , lactate dehydrogenase (LDH-C₄) (O’Hern *et al.*, 1997), which are coded for specific function. Various technologies were implemented to use these proteins as antigens to elicit an immune response which includes genomics, proteomics, vaccinology, hybridization, hybridoma technology, gene knockout technology, etc. (Kaur and Prabha, 2014). Recombinant gene technology was also implemented using *E. coli* to produce sperm antigen-based immunocontraceptives. Passive immunization with either polyclonal

or monoclonal antibodies developed against the sperm proteins (antigens) provided significant contraceptive response and reduced side effects (Reilly, 1999). Monoclonal antibodies (mAbs) produced against the rabbit sperm namely, mouse anti-rabbit sperm (MARS) showed greater contraceptive efficacy upon inseminating the female rabbits with sperm incubated with this mAbs (Castle *et al.*, 1997).

Immunocontraceptives Affecting Gamete Outcome

Fertilisation of sperm and ovum leads to the formation of the gamete. During various steps of pregnancy different types of factors were involved to maintain the viability of the gamete. Among them, human chorionic gonadotrophin (hCG) and Leukemia inhibitory factor (LIF) were considered to have crucial role (Lemons and Naz, 2011). Generation of antibodies against these factors will lead to termination of pregnancy (Kayisli *et al.*, 2003). hCG was produced from the trophoblast of pregnant women and they have two subunits namely, α and β subunits (Hearn *et al.*, 1988). Production of antibodies against the β -subunit of hCG produced the implantation failure in sub human primates (Naz, 2014). To increase the antigenicity of the hCG vaccine, recombinant approach was tried with tetanus toxin (Tandon *et al.*, 1981) and β -subunit of *Escherichia coli* heat-labile enterotoxin (Purswani and Talwar, 2011). LIF was a glycoprotein which belongs to the member of interleukin-6 cytokine family and it was considered to be an essential factor for implantation in different mammalian species (Robb *et al.*, 2002). Sengupta *et al.*, 2006 conducted a study in rhesus monkey by injecting the LIF antibody through intra-peritoneal route between days 3 and 4 after vaginal plug formation resulted in the blockade of embryo implantation. In another study by Lemons and Naz, 2012 there was an inhibition of fertility in the female mice immunized with LIF/LIF-R peptide vaccines and also there was a long-lasting circulating and local antibody response for the vaccine.

Advantages of Immunocontraceptives over Other Methods of Contraception

In previous days, contraception was done by using physical (surgery) and chemical methods (inclusive of endocrinal approach). In surgical approach, castration and spaying were implemented. In females, ovariectomy can lead to complications like hemorrhage, stump pyometra, ovarian remnant syndrome, estrogen-responsive urinary incontinence, stump granuloma and fistula draining tracts. In case of castrated males, “irritable male syndrome” due to sudden withdrawal of testosterone and hernia are reported as complications (Lincoln, 2001 and Howe, 2006). In chemical method, intra-testicular injections of zinc gluconate and calcium chloride were used in males but the safety and efficacy need to be increased by conducting additional field trials (Levy *et al.*, 2008, Oliveira *et al.*, 2012, Fagundes *et al.*, 2014, Jana and Samanta, 2007). In the hormonal method, various hormonal agonists and antagonists are used, but they caused pathological lesions affecting the livability of the subjects Massei and Miller,

(2013). As an alternative approach, immunocontraceptives have been developed in the recent years to reduce these disadvantages. They do not produce any reproductive tract pathology which is a life-threatening one, has a long-term immune response to reduce fertility and has little side effects. In some types of immunocontraceptive vaccines, a single administration is enough to elicit long-term infertility. This technique has been widely used to control the wildlife population explosion due to its easy administration; long-term effect with no surgical intervention is needed (Satish and Vidisha, 2017). Many commercial immunocontraceptive vaccines based on ZP and GnRH are evaluated in animals for its safety and efficacy. They are now proven to be a potential tool in imparting the contraception in animals (Naz and Saver, 2016). But despite of these ample advantages of immunocontraception for population control, this can evolve resistance among the population because the antibody response data from different studies indicated the low heritability for this trait suggesting that contraceptive resistant subjects will also have low heritability for their fertility levels. So we can anticipate the slow evolution of contraceptive resistant in the immunized population in future (Magiafoglou *et al.*, 2003).

Conclusion

In the new era of scientific development, the technology and science interplayed to produce many novel and innovative products. One such novel identification is the immunocontraceptives for controlling the population explosion. Immunocontraceptives are now being widely employed in both animals and humans but more research activities are needed on this aspect to improve the efficacy and safety of the contraceptive vaccine usage. Exploitation of sperm antigens and zona pellucida proteins for the production of contraceptive vaccine should be done to improve the effectiveness in imparting contraception in animals. DNA vaccines based on ZP proteins show added advantage, also production of monoclonal antibodies against sperm antigen act as “cherry” on the top of the cake. So, immunocontraceptives vaccines provide an ample prospect to be used as tool in population control and unwanted pregnancies, an ore to be mined.

References

1. Anderson RP and Jabri B. 2013. Vaccine against autoimmune disease: antigen-specific immunotherapy. *Current Opinon Immunology*. 25:410-417.
2. Balet L, Janett F, Hüsler J, Piechotta M, Howard R, Amatayakul-Chantler S, Steiner A and Hirsbrunner G. 2014. Immunization against gonadotropin-releasing hormone in dairy cattle: antibody titers, ovarian function, hormonal levels, and reversibility. *Journal of Dairy Science*. 97: 2193-2203.
3. Benka VA and Levy JK. 2015. Vaccines for feline contraception: GonaCon GnRH hemocyanin conjugates immunocontraceptive. *Journal of Feline Medicine and Surgery*. 17: 758-765.
4. Bohrer BM, Flowers WL, Kyle JM, Johnson SS, King VL, Spruill JL, Thompson DP, Schroeder AL and Boler DD. 2014. Effect of gonadotropin releasing factor suppression with an immunological on growth performance, estrus cyclicity, carcass characteristics, and meat quality of market gilts. *Journal of Animal Science*. 92: 4719-4724.

5. Castle PE, Whaley KJ, Hoen TE, Moench TR and Cone RA. 1997. Contraceptive effect of sperm-agglutinating monoclonal antibodies in rabbits. *Biology of Reproduction*. 56: 153–159.
6. Cherr GN, Yudin AI, and Overstreet JW. 2001. The dual functions of GPI-anchored PH-20: hyaluronidase and intracellular signaling. *Matrix Biology*. 20: 515–525.
7. Cui X, Duckworth JA, Molinia FC and Cowan PE. 2010. Identification and evaluation of an infertility-associated ZP3 epitope from the marsupial brushtail possum (*Trichosurus vulpecula*). *Vaccine*, 28: 1499–1505.
8. Dalmau A, Velarde A, Rodriguez P, Pedernera C, Lionch P, Fábrega E, Casal N, Mainau E, Gispert M, King V, Sloomans N, Thomas A and Mombarg M. 2015. Use of antiGnRF vaccine to suppress estrus in crossbred Iberian female pigs. *Theriogenology*. 84: 342-347.
9. Diekman AB, Westbrook-Case VA, Naaby-Hansen S, Klotz KL, Flickinger CJ and Herr JC. 1997. Biochemical characterization of sperm agglutination antigen-1, a human sperm surface antigen implicated in gamete interactions. *Biology of Reproduction*. 57: 1136–1144.
10. Diwan M, Dawar H and Talwar GP. 1998. Induction of early and bioeffective antibody response in rodents with the luteinizing hormone-releasing hormone vaccine given as a single dose in biodegradable microspheres along with alum. *Prostate*. 35: 279–284.
11. Fagundes AK, Oliveira EC, Tenorio BM, Melo CC, Nery LT, Santos FA, Alves LC, Douglas RH and Silva Jr VA. 2014. Injection of a chemical castration agent, zinc gluconate, into the testes of cats results in the impairment of spermatogenesis: a potentially irreversible contraceptive approach for this species? *Theriogenology*. 8: 230-236.
12. Ferro VA, Costa R, Carter KC et al., 2004. Immune responses to a GnRH-based anti-fertility immunogen, induced by different adjuvants and subsequent effect on vaccine efficacy. *Vaccine*. 22: 1024–1031.
13. Frayne J and Hall L. 1999. The potential use of sperm antigens as targets for immunocontraception; past, present and future. *Journal of Reproductive Immunology* 43: 1–33.
14. Goudet G, Mugnier S, Callebaut I and Monget P. 2008. Phylogenetic analysis and identification of pseudogenes reveal a progressive loss of zona pellucida genes during evolution of vertebrates. *Biology of Reproduction*. 78: 796–806.
15. Grgac EV and Anderson DA. 2006. Virus-like particles: passport to immune recognition. *Methods*. 40: 60–65.
16. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB and Wang XY. 2013. Therapeutic cancer vaccines: past, present, and future. *Advance Cancer Research*. 119: 421- 475.
17. Gupta SK, Choudhury S, Srivastava N and Ravi C. 2003. Zona pellucida glycoproteins based immunocontraceptive vaccines: Strategies for development and their applications. *Indian Journal of Experimental Biology*. 41: 682 - 693.
18. Hannesdottir SG, Han X, Lund T, Singh M, van der Zee R, Roitt IM and Delveset PJ. 2004. Changes in the reproductive system of male mice immunized with a GnRH-analogue conjugated to mycobacterial hsp70. *Reproduction*. 128; 365–371.
19. Hearn JP, Gidley-Baird AA, Hodges JK, Summers PM and Webley GE. 1988. Embryonic signals during the pre-implantation period in primates. *J. Reprod. Fertil. Suppl*. 36: 49–58.
20. Herr JC, Flickinger CJ, Homyk M, Klotz K and John E. 1990. Biochemical and morphological characterization of the intra acrosomal antigen SP-10 from human sperm. *Biology of Reproduction*. 42: 181–193.
21. Hodges JK and Hearn JP. 1977. Effects of immunisation against luteinising hormone releasing hormone on reproduction of the marmoset monkey *Callithrix jacchus*. *Nature*. 265: 746-748.
22. Howe LM. 2006. Surgical methods of contraception and sterilization. *Theriogenology*. 66: 500-509.
23. Jana K and Samanta PK. 2007. Sterilization of male stray dogs with a single intratesticular injection of calcium chloride: a dose dependent study. *Contraception*. 75, 390–400 (2007)
24. Janet F, Gerig T, Tschuor AC, Amatayakul-Chantler S, Walker J, Howard R, Bollwein H and Thun R. 2012. Vaccination against gonadotropin releasing factor (GnRF) with Bopriva significantly decreases

- testicular development, serum testosterone levels and physical activity in pubertal bulls. *Theriogenology*. 78: 182-188.
25. Joonè CJ, Schulman ML and Bertschinger HJ. 2017. Ovarian dysfunction associated with zona pellucida-based immunocontraceptive vaccines, *Theriogenology*. 89: 329 – 337.
26. Joone CJ, Schulman ML, Fosgate GT, Claes AN, Gupta SK, Botha AE, Human AM and Bertschinger HJ. 2018. Serum anti-Müllerian hormone dynamics in mares following immunocontraception with anti-zona pellucida or -GnRH vaccines. *Theriogenology*. 106: 214 – 220.
27. Kanchan V and Panda AK. 2007. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. *Biomaterials*. 28: 5344–5357.
28. Karaconji B, Lloyd B, Campbell N, Meaney D and Ahern T. 2015. Effect of an antigonadotropin releasing factor vaccine on sexual and aggressive behavior in male pigs during the finishing period under Australian field conditions. *Australian Veterinary Journal*. 93: 121-123.
29. Kaur K and Prabha V. 2014. Immunocontraceptives: New approach to fertility control. *BioMed Research International*.
30. Kayisli U, Selam B, Guzeloglu-Kayisli O, Demir R and Arici A. 2003. Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating fasfas ligand system. *The Journal of Immunology*. 171: 2305–2313.
31. Leitner WW, Ying H and Restifo NP. 1999. DNA and RNA-based vaccines: principles, progress and prospects. *Vaccine* 18:765–777.
32. Lemons AR and Naz RK. 2011. Contraceptive vaccines targeting factors involved in establishment of pregnancy. *American Journal of Reproductive Immunology*. 66: 13–25.
33. Lemons AR and Naz RK. 2012. Birth control vaccine targeting leukemia inhibitory factor. *Mol. Reprod. Dev.* 79: 97–105.
34. Levy JK, Crawford PC, Appel LD and Clifford EL. 2008. Comparison of intratesticular injection of zinc gluconate versus surgical castration to sterilize male dogs. *American Journal of Veterinary Research*. 69: 140–143.
35. Lincoln G. 2001. The irritable male syndrome. *Reproduction, Fertility, and Development*. 13: 567–576.
36. Lugar DW, Rhoads ML, ClarkDeener SG, Callahan SR, Revercomb AK, Prusa KJ and Estienne MJ. 2017. Immunological castration temporarily reduces testis size and function without long term effects on libido and sperm quality in boars. *Animal*. 11: 643-649.
37. Magiafoglou A, Schiffer M, Hoffmann AA and Mckechnie SW. 2003. *Immunology and Cell Biology*. 81: 152–159.
38. Mahi-Brown CA, Huang TT Jr and Yanagimachi R. 1982. Infertility in bitches induced by active immunization with porcine zonae pellucidae. *Journal of Experimental Zoology*. 222:89–95.
39. Massei G and Miller LA. 2013. Nonsurgical fertility control for managing free roaming dog population: A review of products and criteria for field applications. *Theriogenology*. 80: 829-838
40. Massei G, Koon KK, Benton S, Brown R, Gomm M, Orahood DS, Pietravalle S and Eckery DC. 2015. Immunocontraception for managing feral cattle in Hong Kong. *PLoS ONE*. 10:4
41. Miller LA, Fagerstone KA and Eckery DC. 2013. Twenty years of immunocontraception research: lessons learned. *Journal of Zoo and Wildlife Medicine*. 44(4s): S84-S96.
42. Miller LA, Gionfriddo JP, Fagerstone KA, Rhyan JC and Killian GJ. 2008. The single shot GnRH immunocontraceptive vaccine (GonaCon™) in whitetailed deer: comparison of several GnRH preparations. *American Journal of Reproductive Immunology*. 60: 214-223.
43. Miller LA, Johns BE and Killian GJ. 2000. Immunocontraception of white-tailed deer with GnRH vaccine. *The American Journal of Reproductive Immunology*. 44: 266–274.
44. Moudgal NR, Jeyakumar M, Krishnamurthy HN, Sridhar S, Krishnamurthy H and Martin F. 1997. Development of male contraceptive vaccine—a perspective. *Human Reproduction Update*. 3: 335-346.

45. Moudgal NR, Murthy GS, Prasanna Kumar KM, Martin F, Suresh R, Medhamurthy R, Patil S, Sehgal S and Saxena BN. 1997. Responsiveness of human male volunteers to immunization with ovine follicle stimulating hormone vaccine: results of a pilot study. *Human Reproduction*. 12: 457 – 463.
46. Moudgal NR, Ravindranath N, Murthy GS, Dighe RR, Aravindan GR and Martin F. 1992. Long-term contraceptive efficacy of vaccine of ovine follicle-stimulating hormone in male bonnet monkeys (*Macaca radiata*). *Journal of Reproduction and Fertility*. 96: 91–102.
47. Naz RK and Saver AE. 2016. Immunocontraception for animals: current status and future perspective. *American Journal of Reproductive Immunology*. 75: 426–439.
48. Naz RK, Gupta SK, Gupta JC, Vyas HK and Talwar GP. 2005. Recent advances in contraceptive vaccine development. *Human Reproduction*. 20: 3271–3283.
49. Naz RK, Rosenblum BB and Menge AC. 1984. Characterization of a membrane antigen from rabbit testis and sperm isolated by using monoclonal antibodies and effect of its antiserum on fertility. *Proceedings of the National Academy of Sciences of the United States of America*. 81: 857–861.
50. Naz RK. 2006. Antisperm immunity for contraception. *Journal of Andrology*. 27: 153–159.
51. Naz RK. 2011. Contraceptive vaccines: success, status, and future perspective. *The American Journal of Reproductive Immunology*. 66: 2–4.
52. Naz RK. 2014. Recent progress toward development of vaccines against conception Expert Reviews in Vaccines. 13: 145–154.
53. Nishimura H, Kim E, Nakanishi T and Baba T. 2004. Possible function of the ADAM1a/ADAM2 fertilin complex in the appearance of ADAM3 on the sperm surface. *The Journal of Biological Chemistry*. 279: 34957–34962.
54. O'Hern PA, Liang Z, Bambra CS and Goldberg E. 1997. Colinear synthesis of an antigen-specific B-cell epitope with a “promiscuous” tetanus toxin T-cell epitope: a synthetic peptide immunocontraceptive. *Vaccine*. 15: 1761–1766.
55. O'Rand MG and Porter JP. 1982. Purification of rabbit sperm autoantigens by preparative SDS gel electrophoresis: amino acid and carbohydrate content of RSA-1. *Biology of Reproduction*. 27: 713–721.
56. Oliveira EC, Moura MR, de Sá MJ, Silva Jr VA, Kastelic JP, Douglas RH and Marques Jr AP. 2012. Permanent contraception of dogs induced with intratesticular injection of a zinc gluconate based solution. *Theriogenology*. 77: 1056-1063.
57. Purswani S and Talwar GP. 2011. Development of a highly immunogenic recombinant candidate vaccine against human chorionic gonadotropin. *Vaccine*. 29: 2341–2348.
58. R. Reilly. 1999. The making of a magic of magic bullet. *Odyssey*. 5: 14–20.
59. Rao J, Herr JC, Reddi PP, Wolkowicz MJ, Bush LA, Sherman NE, Black M, and Flickingeret CJ. 2003. Cloning and characterization of a novel sperm-associated isoantigen (E-3) with defensin and lectin-like motifs expressed in rat epididymis. *Biology of Reproduction*. 68: 290–301.
60. Rino R and Fabio B. 2011. Use of carrier protein for development of protein/polysaccharide conjugate vaccines and protein/protein conjugate vaccines. *Vaccine design: innovative approaches and novel strategies*. Norfolk, UK: Caister Academic.
61. Remy JJ, Bozon V, Couture L, Goxe B, Salesse R and Garnier J. 1993. Suppression of fertility in male mice by immunization against LH receptor. *Journal of Reproductive Immunology*. 25: 63-79.
62. Robb L, Dimitriadis E, Li R and Salamonsen LA. 2002. Leukemia inhibitory factor and interleukin-11: cytokines with key roles in implantation. *Journal of Reproductive Immunology*. 57: 129–141.
63. Roberts AJ and Reeves JJ. 1989. Reproductive and endocrine changes in ewes actively immunized against luteinizing hormone. *Journal of Reproductive Immunology*. 16: 187–197.
64. Santhanam R, Panda AK, Kumar VS and Gupta SK. 1998. Dog zona pellucida glycoprotein-3 (ZP3): expression in *Escherichia coli* and immunological characterization. *Protein Expression and Purification*. 12: 331– 339.
65. Satish KG and Vidisha M. 2017. Wildlife population management: are contraceptive vaccines a feasible proposition? *Frontiers In Bioscience*. 9: 357 – 374.

66. Satish KG, Srinivasan VA, Suman P, Sriraman R, Nagendrakumar SB, Neha G, Shrestha A, Pooja J and Amulya KP. 2011. Contraceptive Vaccines Based on the Zona Pellucida Glycoproteins for Dogs and Other Wildlife Population Management. American Journal of Reproductive Immunology. 66: 51–62.
67. Schrater AF. 1995. Immunization to regulate fertility: biological and cultural frameworks. Social Science & Medicine. 41: 657–671.
68. Sengupta J, Lalitkumar PG, Najwa AR and Ghosh D. 2006. Monoclonal anti-leukemia inhibitory factor antibody inhibits blastocyst implantation in the rhesus monkey. Contraception. 74: 419–425.
69. Skinner SM, Mills T, Kirchick HJ and Dunbar BS. 1984. Immunization with zona pellucida proteins results in abnormal ovarian follicular differentiation and inhibition of gonadotropin induced steroid secretion. Endocrinology. 115: 2418–2432.
70. Srivastava N, Santhanam R, Sheela P, Mukund S, Thakral SS, Malik BS and Gupta SK. 2002. Evaluation of the immunocontraceptive potential of Escherichia coli-expressed recombinant dog ZP2 and ZP3 in a homologous animal model. Reproduction. 123: 847–857.
71. Stevens JD, Sosa JM, deAvila DM, Oatley JM, Bertrand KP, Gaskins CT and Reeveset JJ. 2005. Luteinizing hormone-releasing hormone fusion protein vaccines block estrous cycle activity in beef heifers. Journal of Animal Science. 83:152–159.
72. Tandon A, Das C, Jaikhani BL and Talwar GP. 1981. Efficacy of antibodies generated by PR-b-hCG-TT to terminate pregnancy in baboons: its reversibility and rescue by medroxyprogesterone acetate. Contraception. 24: 83–95.
73. Walcher P, Cui X, Arrow JA, Scobie S, Molinia FC, Cowan PE, Lubitz W and Duckworth JA. 2008. Bacterial ghosts as a delivery system for zona pellucida-2 fertility control vaccines for brushtail possums (*Trichosurus vulpecula*). Vaccine. 26: 6832–6838.
74. Wood DM, Liu C and Dunbar BS. 1981. Effect of alloimmunization and heteroimmunization with zona pellucida on fertility in rabbits. Biology of Reproduction. 25: 439–450.
75. Yang LH, Li JT, Yan P, Liu HL, Zeng SY, Wu YZ, Liang ZQ and He W. 2011. Follicle-stimulating hormone receptor (FSHR)-derived peptide vaccine induced infertility in mice without pathological effect on reproductive organs. Reproduction, Fertility and Development. 23: 544–550.
76. Yurewicz EC, Sacco AG and Subramanian MG. 1987. Structural characterization of the Mr = 55,000 antigen (ZP3) of porcine oocyte zona pellucida. Purification and characterization of alpha- and beta-glycoproteins following digestion of lactosaminoglycan with endo-beta-galactosidase. Journal of Biological Chemistry. 262: 564–571.
77. Zhang X, Lou YH, Koopman M, Doggett T, Tung KS and Curtiss R. 1997. Antibody responses and infertility in mice following oral immunization with attenuated Salmonella typhimurium expressing recombinant murine ZP3. Biology of Reproduction. 56:33–41.